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Abstract
Background: Studies have shown that hypogonadism is closely related to the development of Type 2 
Diabetes. This study aimed to assess hypogonadism among type 2 diabetic and obese male patients in 
Southwest Nigeria.
Methods: One hundred and twenty men consisting of thirty obese diabetics, thirty non-obese diabetics, 
thirty obese non-diabetics and thirty non-obese non-diabetics, were included in the study. Participants 
were interviewed to obtain data on biodata, reproductive characteristics, and anthropometry. Venous 
Blood was collected for the determination of fasting plasma Glucose, glycated haemoglobin, and 
reproductive hormonal levels. 
Results: The prevalence of hypogonadism in this study was 20.8%. The mean age of all the participants 
was 43.39 ± 5.21, most men being in the 40-44 years age group. In this age group, over a third (40%) of the 
men had low testosterone. Out of the 60 participants who were diabetic, 18 (30%) had low testosterone, 
two-third of whom (66.7%) were obese. Mean testosterone was significantly lower in obese diabetics 
when compared with non-obese diabetics. The mean testosterone and FSH were significantly lower in 
obese non-diabetics as well. Both diabetic and non-diabetic groups had significantly higher estrogen in the 
obese participants, than in the non-obese.
Conclusion: In conclusion, hypogonadism is a common finding among diabetic men, and it occurs in 
higher frequency with coexisting obesity. Hence, a holistic approach in the treatment of male patients with 
hypogonadism, type 2 diabetics and obesity should be considered, in order to safeguard their reproductive 
health.
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Résumé 
Objectif : Des études ont montré que l'hypogonadisme est étroitement lié au développement du diabète de 
type 2. Cette étude visait à évaluer l'hypogonadisme chez les hommes diabétiques et obèses de type 2 dans 
le sud-ouest du Nigéria.
 Méthode: Cent vingt hommes comprenant trente diabétiques obèses, trente diabétiques non obèses, 
trente non diabétiques obèses et trente non diabétiques non obèses ont été inclus dans l'étude. Les 
participants ont été interrogés pour obtenir des données sur les bidonnées, les caractéristiques de 
reproduction et l'anthropométrie. V Enous sang a été prélevé pour la détermination du plasma à jeun de 
glucose, glycolyse de l'hémoglobine, et les niveaux hormonaux de reproduction.
Résultats: La prévalence de l'hypogonadisme dans cette étude était de 20,8%. L'âge moyen de tous les 
participants était de 43,39 ± 5,21, la plupart des hommes étant âgés de 40 à 44 ans. Dans ce groupe d'âge, 
plus d'un tiers (40%) des hommes avaient une faible testostérone. Sur les 60 participants diabétiques, 18 
(30%) avaient une faible testostérone, dont les deux tiers (66,7%) étaient obèses. La testostérone moyenne 
était significativement plus faible chez les diabétiques obèses par rapport aux diabétiques non obèses. La 
testostérone moyenne et la FSH étaient également significativement plus faibles chez les non diabétiques 
obèses. Les groupes diabétiques et non diabétiques avaient des œstrogènes significativement plus élevés 
chez les participants obèses que chez les non obèses.
Conclusion: En conclusion, l'hypogonadisme est une constatation courante chez les hommes diabétiques, 
et il se produit en fréquence plus élevée avec une obésité coexistant. Par conséquent, une approche 
holistique dans le traitement des patients masculins souffrant d'hypogonadisme, de diabétiques de type 2 
et d'obésité devrait être envisagée, afin de protéger leur santé reproductive.
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and biochemical alterations that reduce male 
fertility, the impact of the disease on male 
reproductive health is varied. Sexual disorders, 
such as erectile dysfunction and retrograde 
ejaculation are known to occur in diabetic 
individuals and usually end-up in a reduction of 
sexual appetite that is often attributed to lethergy 
and a certain degree of tiredness associated with 
the hyperglycemic state (13-15). Previous 
researchers have found that the prevalence of 
hypogonadism was not dependent on severity of 
hyperglycemia assessed as glycosylated 
hemoglobin (HbA1c) levels (16). 
The aim of this study was to assess 
hypogonadism among T2DM obese and non-
obese males in Nigeria. This will enable 
clinicians in our environment improve on quality 
of holistic treatment in patients with conditions of 
hypogonadism, T2DM and Obesity.
MATERIALS AND METHODS
Study Setting
The study was conducted at the Dame 
Adebutu Centre for Diabetes Care of the 
Endocrinology, Diabetes and Metabolism 
division, Olabisi Onabanjo University Teaching 
Hospital (OOUTH), Sagamu, Ogun State, 
Southwest Nigeria. The Endocrinology, Diabetes 
and Metabolism division provides services to the 
patients of Sagamu and other satellite towns in 
Ogun state, as well as the neighboring states of 
Lagos, Oyo and Ondo.
Study Design
This was a cross-sectional, comparative, 
hospital-based study.
Recruitment of Participants
One hundred and twenty male 
participants were recruited into the study 
consisting of thirty diabetic obese males, thirty 
diabetic non-obese males, thirty non-diabetic 
obese males and thirty non-diabetic non-obese. 
Research participants were drawn from patients 
of the Dame Adebutu Centre for Diabetes Care of 
the Olabisi Onabanjo University Teaching 
Hospital (OOUTH). Diabetics who are 
hypertensive, smokers and individuals on 
narcotics and steroids were excluded.
Sampling Design
The sample size was calculated using the 
2 2 Cochran formula N=Z pq/d (17). With a 
prevalence of 1.85% based on male prevalence 
rate of T2DM in Abeokuta, Ogun state, Nigeria 
(18). This resulted in a sample size of 27.9 
INTRODUCTION
Diabetes mellitus (DM) is one of the 
most prominent health threats in modern 
societies, affecting about 422 million people 
worldwide, particularly in low- and middle-
income countries (1). It is a chronic condition 
characterized by hyperglycemia, which when 
uncontrolled leads to microvascular damage in 
the major  body systems (2) .   Male 
Hypogonadism also known as testosterone 
deficiency is an endocrine disorder characterized 
by the inability of the testes to produce the male 
sex hormone testosterone, sperm or both (3). 
Hypogonadism may be primarily due to testicular 
failure or from secondary causes attributed to 
Hypotha lamic-P i tu i t a ry -Gonada l  ax i s  
dysfunction. Male Hypogonadism may occur in 
men at any age, an earlier study reported that 
more than 60% of men aged greater than 65 have 
free testosterone levels below the normal values 
for men aged 30 to 35 years (4). 
A closer look into Fertility rates of 
modern societies reveals that the increased 
incidence of Diabetes mellitus has been closely 
associated with falling fertility rates in both males 
and females (5,6). Recent studies have shown that 
hypogonadism is closely related to the 
development of Type 2 Diabetes Mellitus 
(T2DM) (7,8), and obese men with T2DM are 
s ignif icant ly more l ikely to  develop 
hypogonadism, with reported proportions of over 
a third of affected individuals (9). Obesity is a 
proinflammatory state resulting in increased 
release and secretion of proinflammatory 
cytokines and adipokines, free fatty acids, and 
estrogens from adipose tissue. These increases 
are important risk factors that may contribute to 
the development of metabolic syndrome and 
T2DM as well as androgen deficiency (10). 
Epidemiological studies support a bidirectional 
relationship between serum testosterone and 
obesity as well as between testosterone and the 
metabolic syndrome. Low serum total 
testosterone predicts the development of central 
obesity and accumulation of intra-abdominal fat 
(11). Also, low total and free testosterone and Sex 
Hormone Binding Globulin (SHBG) levels are 
associated with an increased risk of developing 
the metabolic syndrome, independent of age and 
obesity (12). Conversely, high BMI, central 
adiposity, and the metabolic syndrome are 
associated with and predict low serum total 
testosterone and to a lesser extent free 
testosterone and SHBG levels (11).
Although there is no doubt that Diabetes 
Mellitus is responsible for several pathological 
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Ethical considerations
Approval for the study was obtained from the 
Health Research and Ethics Committee of 
O O U T H ,  w i t h  r e g i s t r a t i o n  n u m b e r  
OOUTH/HREC/08/10/2012. Written informed 
consents were obtained from all study 
participants. All relevant standards of the Revised 
Declaration of Helsinki were followed.
RESULTS
Sociodemographics
The mean age of all the (120) participants 
that were recruited into the study was 43.39 ± 
5.21 with a range of 35 to 55 years. Most 
participants (38.3%) were between the age of 40 
and 44 years. Other sociodemographic data can 
be found in Table 1. All the diabetic participants 
were on medications, with over half (51.7%) of 
them on metformin and another 35% on both 
metformin and insulin. Majority of the diabetic 
participants (86.7%) had history of Erectile 
Dysfunction. The few non-diabetic participants 
who used medication routinely (6.7%) only used 
multivitamin supplements. Only a small 
percentage of the non-diabetic participants 
(6.7%) had history of erectile dysfunction. Of all 
the participants, 11 (9.2%) had borderline 
Follicle Stimulating Hormone (FSH), 5 (4.2%) 
had borderline Luteinizing Hormone (LH), 25 
(20.8%) had low testosterone and 2 (1.7%) had 
low oestrogen. All others had normal FSH, LH, 
testosterone and oestrogen (see Figure 1). 84.0% 
and 92.0% of the participants who had low 
testosterone, had inappropriately normal FSH 
and LH respectively, while the remaining 16% 
and 8% had borderline FSH and LH respectively.
The age group with the highest frequency of 
borderline FSH was 45-49 years (36.4%), while 
the age group with the highest frequency of 
borderline LH was 40-44 years and 50-55 years. 
About 40% of those aged 40-44 years had low 
testosterone. Oestrogen was normal in all but 2 
participants who had low oestrogen, 1 in the 40-
44 years range, and the other in the 44-49 age 
range. Out of the 60 participants who were 
diabetic (30 – obese; 30 – non-obese), 18 
individuals (30%) had low testosterone, while the 
others had normal testosterone. Two-third of 
them (66.7%) who were diabetic and had low 
testosterone, were obese.
Comparing Means
Details of the means of the Body Mass 
Index (BMI), glycated hemoglobin (HBA1c), 
Fasting Plasma Glucose (FPG), FSH, LH, 
approximated to 30 for each study group.
Data collection
Personal interviews were conducted for each 
participant using a structured questionnaire that 
contained items on reproductive characteristics, 
anthropometric indices and biodata.
Ten (10) mls of blood sample was collected 
from each participant. Five (5) mls, 3mls and 
2mls were dispensed into plain bottle (for assay 
of biochemical assay), EDTA bottle (for 
Haematological Assay) and Fluoride oxalate 
bottle (for Fasting Plasma Glucose) respectively. 
Laboratory procedures
The blood collected was centrifuged at 4000 
rev/min for 10 minutes. The serum from the plain 
bottle was separated into labelled plain bottles 
Oand stored at -20 C until analysis while the 
plasma from fluoride bottle and blood in EDTA 
bottle were analysed within 8hrs of collection.
Assays of blood HbA1c was done by 
the method of ion exchange resin. Serum FSH, 
LH, oestrogen and testosterone assays were 
performed using the Enzyme Immunoassay 
(EIA) kits from Bio-Inteco (UK) Ltd, England. 
Fasting plasma glucose was determined by the 
glucose oxidase method using kits from Randox 
Laboratories Ltd, United Kingdom.
Definition of terms
Hypogonadism was defined as: 
2BMI (Obesity) – 30-34kg/m
HBA1c –  5 .2-5 .6  (Normal ) ,  5 .7 -6 .4  
(Prediabetes), 6.5-7.0 (Diabetes), 7.1-8.4 
(Harmful),        8.5-15 (Dangerous)
FPG – 70-110 mg/dl (normal)
FSH -   <1.0 (low). 1.0-2.0(border), 2.1-
14(normal)
LH –  <0.1(low), 0.1-1.9(border),  2.0-
7.4(normal)
Testosterone -  <3(low),  3-10(normal)
Oestrogen -  <10(low),  10-82(normal) (19). 
Obese participants were defined as participants 
2
with BMI 30 to 34 kg/m  (20) (WHO, 2008).
Statistical analysis
Statistical Package for Social Sciences 
(SPSS), version 20 was used for data input and 
analyses. Chi-square test was used to test for 
significant association between categorical 
variables, while Student's t-test was used to test 
the difference between the means of two groups 
of continuous variables. Statistical significance 
was set at P < 0.05.
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were statistically significant(p < 0.05) (see Table 
2, Table 3).
Non-obese groups (Diabetics Vs Non-
Diabetics)
The non-obese diabetic group had 
normal mean BMI, FSH, LH and oestrogen, 
while the HBA1c was harmfully high, the FPG 
was in the diabetic range and the testosterone was 
low. On the other hand, the means of all the 
anthropometric and biochemical parameters for 
the non-obese non-diabetics (BMI, HBA1c, 
FPG, FSH, LH, testosterone and oestrogen) were 
all within normal limits. The higher HBA1c, FPG 
and oestrogen in the non-obese diabetics was 
statistically significant, as were the lower FSH, 
LH and testosterone (p < 0.05). There was no 
significant difference in the BMI of both groups 
(see Table 2, Table 3). 
Sex hormones and Erectile Dysfunction
Our findings show a significant 
relationship between low testosterone and 
erectile dysfunction (p < 0.05) (see Table 4).
DISCUSSION
Studies have shown that hypogonadism 
can occur at any age, though much more common 
amongst older males (21). One particular study 
reported hypogonadism in over a third of the men 
≥ 45 years, with diabetes being the third 
commonest association, after hypertension and 
hyperlipidemia (22). In our study however, most 
of our participants who had low testosterone were 
slightly younger (in the 40-44 years range). The 
most prevailing pattern of hypogonadism from 
o u r  s t u d y  i s  t h e  h y p o g o n a d o t r o p i c  
hypogonadism, which is characterized by low 
levels of testosterone accompanied by 
inappropriately normal to low FSH and LH. This 
is the same pattern obtainable in similar studies 
amongst diabetics, more so in obese diabetics 
(23).
The mechanism behind this finding is 
complex and likely multifactorial. The 
suppression of the gonadotropins in diabetes is 
postulated to be due to the excessive activity of 
aromatase in the obese which converts the 
androgens in estrogen which can potentially 
inhibit Gonadotropin Releasing Hormone 
(GnRH). Other researchers have however 
disproved this theory (24).
A study showed that one-third of men 
with obesity or type 2 diabetes have subnormal 
free testosterone concentrations. The lower free 
testosterone concentrations are observed in obese 
testosterone and oestrogen can be found in Table 
2.
Diabetic groups (Obese Vs Non-obese)
The mean BMI, FSH, LH and oestrogen of the 
non-obese diabetics were within normal limits. 
However the mean HBA1c in this group was 
within harmful limits, while the FPG and 
testosterone were in the diabetic and low ranges 
respectively. On the other hand, the mean FSH, 
LH and oestrogen of the obese diabetics were 
within normal limits, while the mean BMI was in 
the obese range, and the HBA1c, FPG, and 
testosterone were in the harmful, pre-diabetic and 
low ranges respectively (see Table 2).
The BMI was significantly higher in the 
obese diabetics than in the non-obese diabetics (P 
< 0.05) (Table 3). Mean testosterone level was 
noted to be significantly lower in the obese 
diabetics than in the non-obese diabetics (P < 
0.05) (Table 3). Conversely, the mean oestrogen 
level was significantly higher in the obese 
diabetics than in the non-obese group. There was 
no significant difference in the mean levels of the 
HBA1c, FPG, FSH and LH between the obese 
diabetics and the non-obese diabetics.
Non-diabetic groups
All means of the anthropometric and 
biochemical parameters (BMI, HBA1c, FPG, 
FSH, LH, Testosterone and Oestrogen) were 
within normal limits in the non-obese non-
diabetic groups. Only the mean BMI was 
significantly elevated in the obese non-diabetic 
group (p < 0.05), whereas all other parameters 
were normal. However, the mean FSH and 
testosterone were significantly lower in the obese 
non-diabetics than in the non-obese non-
diabetics (p < 0.05). Conversely, the mean 
oestrogen level was significantly higher in the 
obese non-diabetics than in the non-obese non-
diabetics (p < 0.05) (see Table 2, Table 3).
Obese Groups (Diabetics Vs Non-Diabetics)
The mean FSH, LH and oestrogen levels 
of the obese diabetics were within normal limits, 
while the HBA1c was harmfully high, the FPG 
was in the pre-diabetic range, the testosterone 
was low and the oestrogen was within normal 
limits. Conversely, the obese non-diabetics had 
normal mean HBA1c, FPG, FSH, LH, 
testosterone and oestrogen. The BMI in both 
groups were in the obese range. The lower FSH, 
LH and testosterone observed in the obese 
diabetics were statistically significant. Similarly, 
the higher mean HBA1c, FPG and oestrogen 
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Table 1: Socio-demographic characteristics of Total Participants 
 
Variable Frequency 
(n = 120) 
Percentage 
Age group (in years) 
35-39 31 25.8 
40-44 46 38.3 
45-49 24 20.0 
50-55 19 15.8 
   
Marital Status 
Married 120 100.0 
Not Married 0 0.0 
   
Number of Children 
1 3 2.5 
2 30 25.0 
3 36 30.0 
4 29 24.2 
5 15 12.5 
6 7 5.8 
   
Total 120 100 
 




 (Mean ± SD) 
Obese  Diabetic 
(Mean ± SD) 
Non-Obese 
Non-Diabetic  
(Mean ± SD) 
Obese   
Non-Diabetic   
(Mean ± SD) 
BMI (kg/m2) 22.83 ± 2.57 32.52 ± 1.60 23.11 ± 2.67 32.67 ± 2.37 
HBA1c (%) 7.72 ± 1.43 7.23 ± 1.12 5.17 ± 0.46 5.14 ± 0.42 
FPG 128.87 ± 54.33 113.53 ± 22.29 86.47 ± 6.13 90.63 ± 10.26 
FSH 3.92 ± 1.35 3.77 ± 1.31 7.72 ± 1.20 6.08 ± 2.02 
LH 3.06 ± 0.99 3.17 ± 1.19 5.34 ± 0.93 5.02 ± 1.35 
Testosterone 2.83 ± 0.45 2.57 ± 0.48 5.12 ± 0.74 3.64 ± 1.45 
Oestrogen 20.43 ± 3.31 51.05 ± 8.81 12.08 ± 1.78 41.40 ± 13.20  
 
Reference ranges 
BMI (Obesity) – 30-34kg/m2 
HBA1c –  5.2-5.6(Normal),  5.7-6.4 (Prediabetes),  6.5-7.0(Diabetes),  7.1-8.4(Harmful),  
8.5-15(Dangerous) 
FPG – 70-110 mg/dl (normal) 
FSH -   <1.0 (low). 1.0-2.0(border),  2.1-14(normal) 
LH –  <0.1(low), 0.1-1.9(border),  2.0-7.4(normal) 
Testosterone -  <3(low),  3-10(normal) 
Oestrogen -  <10(low),  10-82(normal) 
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x Obese Diabetic  
T-test (p-value) 









Diabetic x Obese 
Non-Diabetic 
T-test (p-value) 
BMI (kg/m2) -17.25 (0.00*) -0.29 (0.78) -0.41 (0.68) 14.53 (0.00*) 
HBA1c (%) 1.47 (0.15) 9.40 (0.00*) 9.15 (0.00*) -0.25 (0.79) 
FPG 1.41 (0.17) 5.03 (0.00*) 4.18 (0.00*) 1.88 (0.06) 
FSH 0.43 (0.67) -5.16 (0.00*) -11.34 (0.00*) -3.76 (0.00*) 
LH -0.41 (0.69) -5.51 (0.00*) -9.07 (0.00*) -1.06 (0.29) 
Testosterone 2.10 (0.04*) -3.78 (0.00*) -14.16 (0.00*) -4.87 (0.00*) 
Oestrogen -17.51 (0.00*) -3.27 (0.00*) 11.95 (0.00*) 11.85 (0.00*) 
 
*Statistically significant at p < 0.05 
 
 
Table 4 Association between Biochemical Parameters and Erectile Dysfunction 
 
Variable  Erectile Dysfunction 
Frequency (%) 
÷2 P-value 
Yes (n = 52) No (n = 8) 
HBA1c (%) 




Diabetes (6.5-7.0) 9(100.0) 0(0) 
Harmful (7.1-8.4) 20(95.2) 1(4.8) 
Dangerous (8.5-15) 13(92.9) 1(7.1) 
 
FSH (mIU/L) 
Bordeline (1.0-2.0) 5(100.0) 0(0) 1.50 0.48 
Normal (2.1-14) 47(85.5) 8(14.5) 




11(91.7) 1(8.3) 0.36 0.49 
Normal (2.0-7.4)  41(85.4) 7(14.6) 
     
Testosterone (ng/ml) 
Low (<3) 34(94.4) 2(5.6) 4.68 0.04* 
Normal (3-10) 18(75.0) 6(25.0) 
 
*Statistically significant 
 ÷2–Chi square 
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Figure 1 - Frequency distribution of Sex Hormone levels amongst Study Participants 
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